UnknownPhase 2NCT05281068

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Studying Autoimmune thrombocytopenia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University People's Hospital
Principal Investigator
Xiao-Hui Zhang, MD
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology
Intervention
Iguratimod(drug)
Enrollment
120 enrolled
Eligibility
18-70 years · All sexes
Timeline
2021 – 2023

Study locations (2)

Collaborators

Beijing Hospital · China-Japan Friendship Hospital · Beijing Friendship Hospital · The First Affiliated Hospital of Zhengzhou University · First Affiliated Hospital of Chongqing Medical University · Shanxi Bethune Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05281068 on ClinicalTrials.gov

Other trials for Autoimmune thrombocytopenia

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune thrombocytopenia →

← Back to all trials